001043479 001__ 1043479
001043479 005__ 20250916131807.0
001043479 0247_ $$2doi$$a10.1038/s41467-025-59295-z
001043479 0247_ $$2datacite_doi$$a10.34734/FZJ-2025-02882
001043479 0247_ $$2pmid$$a40324978
001043479 0247_ $$2WOS$$aWOS:001482771100001
001043479 037__ $$aFZJ-2025-02882
001043479 082__ $$a500
001043479 1001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b0
001043479 245__ $$aOral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial
001043479 260__ $$a[London]$$bSpringer Nature$$c2025
001043479 3367_ $$2DRIVER$$aarticle
001043479 3367_ $$2DataCite$$aOutput Types/Journal article
001043479 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1750921863_7812
001043479 3367_ $$2BibTeX$$aARTICLE
001043479 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001043479 3367_ $$00$$2EndNote$$aJournal Article
001043479 520__ $$aSelf-replicating amyloid beta (Aβ) oligomers are considered as one of the major drivers for disrupted synaptic function and plasticity, leading to impaired neuronal viability and progression of Alzheimer’s disease (AD). Here, we investigated the safety, tolerability and pharmacokinetics of the anti-oligomeric peptide PRI-002, which was developed to disassemble toxic Aβ oligomers into non-toxic monomers. In a randomized, double-blind, single-center phase 1b trial, 20 patients aged between 50 and 80 years, with mild neurocognitive impairment (MCI) or mild dementia due to AD were recruited. Eligible patients were randomly assigned (1:1) to receive 300 mg PRI-002 once daily (q.d.) or placebo for 28 days. During treatment, study visits were performed on baseline (Day 1), Day 14, Day 28 and an additional follow-up visit on Day 56. Safety assessments were carried out at all visits to determine the primary endpoints. On Day 7 and Day 21 additional phone visits were carried out to assess concomitant meds and AEs. Primary endpoints were nature, frequency, severity, and timing of adverse and serious adverse events (AE/SAEs) and treatment discontinuation. Furthermore, standard laboratory values, electrocardiogram (ECG), electroencephalogram (EEG), magnetic resonance imaging (MRI), and vital signs were assessed. Secondary endpoints included the evaluation of pharmacokinetic characteristics of PRI-002 in plasma and the determination of cerebrospinal fluid (CSF) concentrations of PRI-002. The trial is registered in EudraCT 2020-003416-27 and clinicaltrials.gov NCT04711486. In the study, 19 out of 20 patients were randomly assigned to PRI-002 (n = 9) or placebo (n = 10) and completed the study. One patient withdrew informed consent before randomization. All primary endpoints were met. Overall, the study drug was well tolerated. In total n = 16 AEs were reported in the verum group, while n = 27 AEs were noted in the placebo group. No SAEs were reported. No significant changes in clinical chemistry, hematology or hematoserology were detected. ECG, EEG and MRI revealed no changes and in detail no ARIA were observed. Pharmacokinetic parameters were unrelated to sex, age, and weight. Furthermore, no significant changes were detected in p-tau, t-tau, Aβ 1-40, Aβ 1-42 and Aβ oligomers in CSF. Patients receiving PRI-002 performed significantly better than those receiving placebo in the CERAD word list at Day 56 (P ≤ 0.05). In conclusion, 28 days of treatment with 300 mg q.d. PRI-002 was well tolerated in patients with MCI or mild dementia due to AD.
001043479 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x0
001043479 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001043479 7001_ $$0P:(DE-HGF)0$$aCosma, Nicoleta Carmen$$b1
001043479 7001_ $$00009-0002-3816-7933$$aKauselmann, Gunther$$b2
001043479 7001_ $$00000-0002-9949-3540$$aFenski, Friederike$$b3
001043479 7001_ $$0P:(DE-HGF)0$$aBieniek, Christine$$b4
001043479 7001_ $$0P:(DE-Juel1)162212$$aBujnicki, Tuyen$$b5
001043479 7001_ $$0P:(DE-Juel1)171619$$aPils, Marlene$$b6
001043479 7001_ $$0P:(DE-Juel1)157832$$aBannach, Oliver$$b7
001043479 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b8$$eCorresponding author
001043479 7001_ $$0P:(DE-HGF)0$$aPeters, Oliver$$b9$$eCorresponding author
001043479 773__ $$0PERI:(DE-600)2553671-0$$a10.1038/s41467-025-59295-z$$gVol. 16, no. 1, p. 4180$$n1$$p4180$$tNature Communications$$v16$$x2041-1723$$y2025
001043479 8564_ $$uhttps://juser.fz-juelich.de/record/1043479/files/s41467-025-59295-z-1.pdf$$yOpenAccess
001043479 8767_ $$8SN-2025-00897-b$$92025-08-27$$a1200217075$$d2025-09-15$$eAPC$$jZahlung erfolgt
001043479 8767_ $$8SN-2025-00897-b$$92025-08-27$$a1200217075$$d2025-09-15$$eAPC$$jZahlung angewiesen
001043479 909CO $$ooai:juser.fz-juelich.de:1043479$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire
001043479 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b0$$kFZJ
001043479 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162212$$aForschungszentrum Jülich$$b5$$kFZJ
001043479 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171619$$aForschungszentrum Jülich$$b6$$kFZJ
001043479 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)157832$$aForschungszentrum Jülich$$b7$$kFZJ
001043479 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b8$$kFZJ
001043479 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
001043479 9141_ $$y2025
001043479 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001043479 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNAT COMMUN : 2022$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT COMMUN : 2022$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-30T07:48:07Z
001043479 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-30T07:48:07Z
001043479 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
001043479 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001043479 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2024-01-30T07:48:07Z
001043479 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)1060$$2StatID$$aDBCoverage$$bCurrent Contents - Agriculture, Biology and Environmental Sciences$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2025-01-02
001043479 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
001043479 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001043479 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
001043479 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
001043479 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
001043479 915pc $$0PC:(DE-HGF)0113$$2APC$$aDEAL: Springer Nature 2020
001043479 920__ $$lyes
001043479 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
001043479 9801_ $$aFullTexts
001043479 980__ $$ajournal
001043479 980__ $$aVDB
001043479 980__ $$aUNRESTRICTED
001043479 980__ $$aI:(DE-Juel1)IBI-7-20200312
001043479 980__ $$aAPC